Cell Therapeutics, Inc. Reports Fourth Quarter And Full Year 2013 Financial Results

SEATTLE, March 4, 2014 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today reported financial results for the fourth quarter and full year ended December 31, 2013.

"2013 was a transformational year for CTI, as we entered into a worldwide license agreement with Baxter International to develop and commercialize our JAK2/FLT3 inhibitor, pacritinib, achieved favorable reimbursement and market access for PIXUVRI in major European markets and reported new positive interim data for tosedostat," stated James A. Bianco, M.D., President and CEO."

Help employers find you! Check out all the jobs and post your resume.